{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:28:28Z","timestamp":1790155708657,"version":"4.0.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"vor","delay-in-days":630,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemistry & Biology"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.chembiol.2011.10.012","type":"journal-article","created":{"date-parts":[[2011,12,22]],"date-time":"2011-12-22T11:20:07Z","timestamp":1324552807000},"page":"1521-1526","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["The Molecular Basis of Pharmacological Chaperoning in Human \u03b1-Galactosidase"],"prefix":"10.1016","volume":"18","author":[{"given":"Abigail\u00a0I.","family":"Guce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel\u00a0E.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome\u00a0J.","family":"Rogich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott\u00a0C.","family":"Garman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chembiol.2011.10.012_bib1","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1046\/j.1432-1327.2000.01457.x","article-title":"In\u00a0vitro inhibition and intracellular enhancement of lysosomal \u03b1-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives","volume":"267","author":"Asano","year":"2000","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.chembiol.2011.10.012_bib2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ymgme.2006.01.010","article-title":"Lysosomal storage diseases: natural history and ethical and economic aspects","volume":"88","author":"Beutler","year":"2006","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.chembiol.2011.10.012_bib3","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2011.10.012_bib4","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/nature02265","article-title":"Therapeutic approaches to protein-misfolding diseases","volume":"426","author":"Cohen","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2011.10.012_bib5","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3733","article-title":"Galactosidase A deficiency: Fabry disease","author":"Desnick","year":"2001"},{"key":"10.1016\/j.chembiol.2011.10.012_bib6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/humu.1380030204","article-title":"Molecular basis of Fabry disease: mutations and polymorphisms in the human \u03b1-galactosidase A gene","volume":"3","author":"Eng","year":"1994","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.chembiol.2011.10.012_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human \u03b1-galactosidase A\u2014replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2011.10.012_bib8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0165-6147(03)00158-5","article-title":"A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity","volume":"24","author":"Fan","year":"2003","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.chembiol.2011.10.012_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/BC.2008.009","article-title":"A counterintuitive approach to treat enzyme deficiencies: use\u00a0of enzyme inhibitors for restoring mutant enzyme activity","volume":"389","author":"Fan","year":"2008","journal-title":"Biol. Chem."},{"key":"10.1016\/j.chembiol.2011.10.012_bib10","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1111\/j.1742-4658.2007.06041.x","article-title":"Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors","volume":"274","author":"Fan","year":"2007","journal-title":"FEBS J."},{"key":"10.1016\/j.chembiol.2011.10.012_bib11","article-title":"Inhibitors enhance lysosomal \u03b1-galactosidase A activity in Fabry lymphoblasts: a possible molecular therapy for a genetic disorder","volume":"8","author":"Fan","year":"1998","journal-title":"Glycobiology"},{"key":"10.1016\/j.chembiol.2011.10.012_bib12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","article-title":"Accelerated transport and maturation of lysosomal \u03b1-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor","volume":"5","author":"Fan","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.chembiol.2011.10.012_bib13","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ymgme.2010.03.019","article-title":"DLHex-DGJ, a novel derivative of 1-deoxygalactonojirimycin with pharmacological chaperone activity in human G(M1)-gangliosidosis fibroblasts","volume":"100","author":"Fantur","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.chembiol.2011.10.012_bib14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1056\/NEJM200107053450104","article-title":"Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy","volume":"345","author":"Frustaci","year":"2001","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2011.10.012_bib15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1096-7192(02)00151-8","article-title":"Structural basis of Fabry disease","volume":"77","author":"Garman","year":"2002","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.chembiol.2011.10.012_bib16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jmb.2004.01.035","article-title":"The molecular defect leading to Fabry disease: structure of human \u03b1-galactosidase","volume":"337","author":"Garman","year":"2004","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.chembiol.2011.10.012_bib17","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1074\/jbc.M109.060145","article-title":"Catalytic mechanism of human \u03b1-galactosidase","volume":"285","author":"Guce","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.chembiol.2011.10.012_bib18","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4172\/jpb.1000128","article-title":"Molecular basis of chemical chaperone effects of N-octyl-\u03b2-valienamine on human \u03b2-glucosidase in low\/neutral pH conditions","volume":"3","author":"Jo","year":"2010","journal-title":"J Proteomics Bioinform"},{"key":"10.1016\/j.chembiol.2011.10.012_bib19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0008-6215(00)90138-1","article-title":"Synthesis of 5-amino-5-deoxy-D-galactopyranose and 1,5-dideoxy-1,5-imino-D-galactitol, and their inhibition of \u03b1- and \u03b2-D-galactosidases","volume":"155","author":"Legler","year":"1986","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.chembiol.2011.10.012_bib20","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1021\/bi9002265","article-title":"Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability","volume":"48","author":"Lieberman","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.chembiol.2011.10.012_bib21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/BF00223869","article-title":"\u03b1-Galactosidase gene mutations in Fabry disease: heterogeneous expressions of mutant enzyme proteins","volume":"95","author":"Okumiya","year":"1995","journal-title":"Hum. Genet."},{"key":"10.1016\/j.chembiol.2011.10.012_bib22","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/emmm.200900036","article-title":"Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics","volume":"1","author":"Parenti","year":"2009","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.chembiol.2011.10.012_bib23","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/BF00484919","article-title":"Residual activity of \u03b1-galactosidase A in Fabry's disease","volume":"13","author":"Romeo","year":"1975","journal-title":"Biochem. Genet."},{"key":"10.1016\/j.chembiol.2011.10.012_bib24","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.chembiol.2005.09.007","article-title":"Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles","volume":"12","author":"Sawkar","year":"2005","journal-title":"Chem. Biol."},{"key":"10.1016\/j.chembiol.2011.10.012_bib25","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.chembiol.2011.10.012_bib26","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4137\/PMC.S2332","article-title":"Chaperone therapy for neuronopathic lysosomal diseases: competitive inhibitors as chemical chaperones for enhancement of mutant enzyme activities","volume":"3","author":"Suzuki","year":"2009","journal-title":"Perspect Medicin Chem"},{"key":"10.1016\/j.chembiol.2011.10.012_bib27","doi-asserted-by":"crossref","first-page":"14504","DOI":"10.1016\/S0021-9258(18)98715-6","article-title":"Chemical modification of the glucosidase inhibitor 1-deoxynojirimycin. Structure-activity relationships","volume":"266","author":"Tan","year":"1991","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.chembiol.2011.10.012_bib28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1096\/fj.04-2375com","article-title":"A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder","volume":"19","author":"Yam","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.chembiol.2011.10.012_bib29","doi-asserted-by":"crossref","first-page":"C1076","DOI":"10.1152\/ajpcell.00426.2005","article-title":"Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants","volume":"290","author":"Yam","year":"2006","journal-title":"Am. J. Physiol. Cell Physiol."}],"container-title":["Chemistry & Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074552111003978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074552111003978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T07:17:07Z","timestamp":1761031027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1074552111003978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S1074552111003978"],"URL":"https:\/\/doi.org\/10.1016\/j.chembiol.2011.10.012","relation":{},"ISSN":["1074-5521"],"issn-type":[{"value":"1074-5521","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Molecular Basis of Pharmacological Chaperoning in Human \u03b1-Galactosidase","name":"articletitle","label":"Article Title"},{"value":"Chemistry & Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chembiol.2011.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}